Central serous chorioretinopathy following oral tadalafil

Eye

Volumn 26, Issue 1, 2012, Pages 168-169

  Gordon Bennett, P ^a   Rimmer, T ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b PETERBOROUGH CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; TADALAFIL;

ADULT; CASE REPORT; CENTRAL SEROUS RETINOPATHY; CHOROID VASCULARIZATION; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; OPHTHALMOSCOPY; PENIS ERECTION; POSTMARKETING SURVEILLANCE; RETINA DETACHMENT; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84855846297     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.250     Document Type: Letter

References (4)

1. French DD, Margo CE. Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 2010; 30(2): 271-274.
2. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121: 26-34. (Pubitemid 26026078)
3. Klais C, Ober M, Ciardella A, Yannuzzi L. Central serous chorioretinopathy. In: Ryan S (ed). Retina, 4th edn, Vol 2, Elsevier/Mosby: Philadelphia, 2006, pp 1135-1139.
4. Cordell WH, Maturi RK, Costigan TM, Marmor MF, Weleber RG, Coupland SG et al. ERG Testing During Chronic PDE5 Inhibitor Administration (ERG-PDE5i) Consortium. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol 2009; 127(4): 367-373.